ImmunityBio, Inc. (IBRX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms.
Is ImmunityBio, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, ImmunityBio, Inc. (IBRX) trades at $8.29 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: ImmunityBio, Inc.
Market cap $9B · 52 weeks $2 – $12 (28 % below the high) · P/E no earnings · Dividend none · Next earnings November 3, 2026 · expected EPS -$0.07 · Closing price, Oct 30 · accounts published Aug 4.
- Valuation: P/Sales 130× (no earnings).
- Balance sheet: Distress zone (fragile).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 0 of 4 pass
- Cash Runway 10 months, fails.
- Total Debt 4.1×, fails.
- R&D / Market cap 2.7 %, fails.
- Market cap / Cash 31.4×, fails.
- Annual cash burn $0.33, info.
Against its peers (reference peers) — ImmunityBio, Inc.: P/E —; EV/EBITDA —; ROIC -45.0 %; $8.8B. TG Therapeutics, Inc. (P/E 22.3×; EV/EBITDA 71.8×; ROIC 9.9 %; $9.4B), Protagonist Therapeutics, Inc. (P/E 140×; EV/EBITDA 104×; ROIC 6.7 %; $9.4B), Caris Life Sciences, Inc. (P/E 95.9×; EV/EBITDA 54.8×; ROIC 14.7 %; $9.7B).
Profitability
| Return on Equity | 134.99% |
| Return on Invested Capital | -45.01% |
| Return on Assets | -157.89% |
| Gross Margin | 94.63% |
| Operating Margin | -151.88% |
| Net Margin | -598.56% |
Financial Health
| Debt / Equity | -0.78 |
| Current Ratio | 5.72 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -10.16 |
Price Performance
| 1 month | -19.44% |
| 3 months | +19.28% |
| Year-to-date | +318.69% |
| 1 year | +245.42% |
| 3 years | +121.07% |
| 5 years | -5.37% |
| 10 years | +39.09% |
Related companies: BNTX · MRNA · LEGN · IOVA
Explore sector: Healthcare · Biotechnology
More sections of IBRX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks